불면증 시장 : 경쟁 분석(2026년)

The Insomnia competitive landscape continues to evolve as companies focus on developing safer and more effective therapies, expanding product portfolios, pursuing strategic collaborations, and strengthening market access through regulatory approvals and commercialization initiatives.

Insomnia is one of the most common sleep disorders, affecting millions of individuals worldwide and significantly impacting physical health, mental well-being, productivity, and quality of life. Although several pharmacological and non-pharmacological treatment options are available, growing concerns regarding long-term safety, dependence, and treatment efficacy continue to drive innovation. Competitive intelligence analysis provides comprehensive insights into market participants, product portfolios, pipeline developments, strategic partnerships, licensing activities, mergers and acquisitions, regulatory approvals, commercialization strategies, and emerging competitive trends.

Market Drivers

Growing Prevalence of Insomnia

The increasing incidence of chronic insomnia associated with stress, anxiety, depression, aging populations, and changing lifestyles continues to drive demand for innovative therapies. Rising diagnosis rates are encouraging pharmaceutical companies to strengthen their insomnia portfolios and invest in differentiated products.

Expansion of Innovative Sleep Therapies

The insomnia treatment landscape is shifting toward next-generation therapies such as dual orexin receptor antagonists (DORAs), which offer improved efficacy with lower risks of dependence compared with traditional sedative-hypnotics. This transition is intensifying competitive activity across the market.

Increasing Strategic Collaborations

Pharmaceutical companies are actively pursuing licensing agreements, co-development partnerships, acquisitions, and commercialization alliances to strengthen product pipelines, accelerate clinical development, and expand global market presence.

Growth of Digital Sleep Health

Digital therapeutics, cognitive behavioral therapy for insomnia (CBT-I), wearable sleep monitoring devices, and artificial intelligence-based sleep management solutions are creating new opportunities for companies seeking competitive differentiation.

Market Restraints

Generic Competition

The availability of low-cost generic insomnia medications creates pricing pressure and intensifies competition for branded therapies.

Regulatory Challenges

Novel insomnia therapies require comprehensive clinical evidence demonstrating long-term efficacy, safety, and minimal abuse potential before receiving regulatory approval.

Reimbursement Pressure

Healthcare payers increasingly evaluate the cost-effectiveness of new insomnia treatments, creating additional challenges for premium-priced innovative therapies.

Competitive Intelligence Insights

The global insomnia competitive intelligence market can be segmented by company type, product portfolio, therapeutic class, strategic activity, and geography.

By company type, the competitive landscape includes multinational pharmaceutical companies, biotechnology firms, specialty CNS companies, digital health providers, and emerging biotechnology startups. Large pharmaceutical companies continue to dominate commercial markets, while biotechnology firms increasingly contribute innovative pipeline assets.

By therapeutic class, competition spans dual orexin receptor antagonists (DORAs), benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), melatonin receptor agonists, antidepressants used for insomnia, and emerging non-pharmacological therapies. Growing clinical preference for orexin-based therapies is reshaping the competitive landscape.

By strategic activity, competitive intelligence evaluates product launches, licensing agreements, mergers and acquisitions, research collaborations, clinical development, regulatory approvals, patent strategies, commercialization initiatives, and geographic expansion.

Technological advances including artificial intelligence, digital therapeutics, wearable sleep monitoring, remote patient monitoring, real-world evidence, and advanced analytics are increasingly influencing competitive positioning and product differentiation.

Competitive Development Trends

The insomnia competitive landscape continues to evolve through continuous innovation and strategic business activities.

Key competitive trends include:

• Expansion of dual orexin receptor antagonist portfolios.
• Growing investment in digital therapeutics and CBT-I platforms.
• Increased licensing and partnership agreements.
• Greater emphasis on real-world evidence generation.
• Expansion into emerging healthcare markets.
• Increased use of artificial intelligence in drug discovery.
• Development of personalized sleep medicine solutions.

Companies are also strengthening competitive positioning through lifecycle management strategies, label expansions, combination therapies, and improved patient support programs.

Regional Insights

North America remains the leading market for insomnia therapeutics due to high diagnosis rates, advanced healthcare infrastructure, strong pharmaceutical innovation, favorable reimbursement for innovative therapies, and significant investment in CNS drug development.

Europe continues to maintain a strong competitive position through robust regulatory systems, established pharmaceutical companies, growing adoption of innovative sleep therapies, and increasing investment in neurological and psychiatric research.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare expenditure, rising awareness of sleep disorders, improving access to specialty care, increasing pharmaceutical investment, and growing adoption of digital healthcare across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening market opportunities through healthcare modernization, expanding pharmaceutical distribution networks, and improving diagnosis of sleep disorders.

Competitive Landscape

The insomnia competitive intelligence landscape includes multinational pharmaceutical companies, biotechnology firms, digital health providers, academic institutions, and specialty CNS developers.

Industry participants continue investing in next-generation orexin receptor antagonists, precision medicine, digital therapeutics, wearable sleep technologies, artificial intelligence-enabled drug discovery, and real-world evidence generation. Strategic collaborations, licensing agreements, mergers and acquisitions, co-promotion partnerships, and commercialization alliances remain central to maintaining competitive advantage.

Competition increasingly focuses on therapies that provide improved efficacy, reduced dependence risk, enhanced patient adherence, and better long-term safety profiles.

Future Outlook

The future of the insomnia competitive intelligence market is expected to be shaped by advances in neuroscience, precision medicine, digital therapeutics, artificial intelligence, and personalized sleep management. Companies are expected to increasingly differentiate themselves through innovative mechanisms of action, integrated digital health solutions, pharmacoeconomic evidence, and patient-centered care models.

Continued investment in orexin biology, digital behavioral therapies, wearable monitoring technologies, and real-world evidence is expected to strengthen competitive positioning while accelerating commercialization of innovative insomnia treatments.

Conclusion

The global Insomnia Competitive Intelligence Analysis market is expected to experience sustained growth through 2035, supported by increasing prevalence of insomnia, expanding development of innovative therapies, advances in sleep medicine, and growing strategic activity among pharmaceutical and biotechnology companies. Although challenges related to generic competition, pricing pressure, and regulatory complexity remain, continued innovation in orexin receptor antagonists, digital therapeutics, artificial intelligence, and precision medicine is expected to reshape the competitive landscape and create significant opportunities for industry participants.

Key Benefits of this Report

• Comprehensive analysis of the global competitive landscape for insomnia therapeutics.
• Detailed assessment of company strategies, product portfolios, and pipeline developments.
• Competitive benchmarking of strategic collaborations, licensing agreements, and mergers and acquisitions.
• Insights into regulatory developments, commercialization strategies, and future market opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, investors, healthcare providers, consultants, and policymakers.

What Businesses Use Our Reports For

Competitive benchmarking, portfolio optimization, licensing and partnership evaluation, merger and acquisition analysis, investment planning, commercialization strategy, market entry assessment, regulatory planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the insomnia competitive landscape by company type, therapeutic class, strategic activity, and geography
• Evaluation of company profiles, product portfolios, pipeline assets, regulatory approvals, and commercialization strategies
• Assessment of licensing agreements, partnerships, mergers and acquisitions, patent activities, and competitive positioning
• Analysis of emerging technologies, digital therapeutics, artificial intelligence, precision medicine, and future competitive opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market and Pipeline Snapshot
  • 1.1.1 Global Insomnia Pipeline Overview
  • 1.1.2 Total Active Assets by Development Phase
  • 1.1.3 Total Active Sponsors by Development Stage
  • 1.1.4 Pipeline Maturity Assessment
  • 1.1.5 Key Competitive Intelligence Findings
• 1.2 Strategic Insights
  • 1.2.1 Emerging Competitive Themes
  • 1.2.2 Innovation Hotspots
  • 1.2.3 Key Development Risks
  • 1.2.4 Near-Term Regulatory Catalysts
  • 1.2.5 Future Competitive Outlook
• 1.3 Executive Dashboard
  • 1.3.1 Top Assets by Commercial Potential
  • 1.3.2 Top Assets by Probability of Success
  • 1.3.3 Top Sponsors by Pipeline Strength
  • 1.3.4 Top Mechanisms of Action
  • 1.3.5 Most Attractive Development Opportunities

2. Pipeline Overview

• 2.1 Report Scope and Coverage
  • 2.1.1 Pipeline Inclusion Criteria
  • 2.1.2 Asset Validation Framework
  • 2.1.3 Data Sources and Verification Methodology
  • 2.1.4 Competitive Intelligence Methodology
• 2.2 Pipeline Landscape Overview
  • 2.2.1 Total Pipeline Assets
  • 2.2.2 Active Versus Discontinued Assets
  • 2.2.3 Historical Pipeline Growth Trends
  • 2.2.4 Pipeline Evolution Timeline
• 2.3 Development Stage Distribution
  • 2.3.1 Preclinical Assets
  • 2.3.2 Phase I Assets
  • 2.3.3 Phase II Assets
  • 2.3.4 Phase III Assets
  • 2.3.5 Filed and Under Review Assets
• 2.4 Sponsor Landscape
  • 2.4.1 Large Pharmaceutical Companies
  • 2.4.2 Mid-Sized Biopharmaceutical Companies
  • 2.4.3 Emerging Biotechnology Companies
  • 2.4.4 Academic and Institutional Sponsors

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Definition and Classification
  • 3.1.2 Acute Insomnia
  • 3.1.3 Chronic Insomnia
  • 3.1.4 Comorbid Insomnia
  • 3.1.5 Treatment-Resistant Insomnia
• 3.2 Epidemiology and Disease Burden
  • 3.2.1 Global Patient Population
  • 3.2.2 Diagnosed Population
  • 3.2.3 Treated Population
  • 3.2.4 Disease Burden Assessment
  • 3.2.5 Quality-of-Life Impact
• 3.3 Current Treatment Landscape
  • 3.3.1 Pharmacological Therapies
  • 3.3.2 Behavioral Therapies
  • 3.3.3 Combination Treatment Approaches
  • 3.3.4 Treatment Algorithm Review
• 3.4 Unmet Needs Driving Innovation
  • 3.4.1 Sleep Onset Challenges
  • 3.4.2 Sleep Maintenance Challenges
  • 3.4.3 Daytime Function Impairment
  • 3.4.4 Long-Term Safety Concerns
  • 3.4.5 Dependence and Tolerance Concerns

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Orexin Pathway Modulation
  • 4.1.2 GABAergic Modulation
  • 4.1.3 Melatonin Receptor Modulation
  • 4.1.4 Circadian Rhythm Regulation
  • 4.1.5 Novel CNS Mechanisms
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Asset Distribution by Mechanism
  • 4.2.2 Mechanism Saturation Analysis
  • 4.2.3 Mechanism Innovation Index
  • 4.2.4 White Space Opportunities
• 4.3 Innovation Assessment
  • 4.3.1 First-in-Class Candidates
  • 4.3.2 Best-in-Class Candidates
  • 4.3.3 Incremental Innovation Programs
  • 4.3.4 Platform-Based Innovation
• 4.4 Modality Landscape
  • 4.4.1 Small Molecule Assets
  • 4.4.2 Biologic Assets
  • 4.4.3 RNA Therapeutic Assets
  • 4.4.4 Cell and Gene Therapy Programs
  • 4.4.5 Digital Therapeutic Integration

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Total Active Clinical Trials
  • 5.1.2 Historical Clinical Trial Trends
  • 5.1.3 Trial Initiation Trends
  • 5.1.4 Trial Completion Trends
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Analysis
  • 5.2.2 Study Duration Analysis
  • 5.2.3 Randomization Approaches
  • 5.2.4 Control Arm Benchmarking
  • 5.2.5 Adaptive Trial Design Adoption
• 5.3 Endpoint Intelligence
  • 5.3.1 Primary Endpoint Benchmarking
  • 5.3.2 Secondary Endpoint Benchmarking
  • 5.3.3 Patient-Reported Outcomes
  • 5.3.4 Objective Sleep Metrics
  • 5.3.5 Regulatory Endpoint Preferences
• 5.4 Operational Intelligence
  • 5.4.1 Recruitment Timelines
  • 5.4.2 Enrollment Rates
  • 5.4.3 Dropout Trends
  • 5.4.4 Site Utilization Analysis
  • 5.4.5 Geographic Enrollment Distribution
• 5.5 Clinical Success Intelligence
  • 5.5.1 Success Rates by Phase
  • 5.5.2 Failure Rates by Phase
  • 5.5.3 Terminated Program Analysis
  • 5.5.4 Risk Factor Assessment

6. Pipeline Segmentation Analysis

• 6.1 Pipeline Segmentation by Development Phase
  • 6.1.1 Preclinical Pipeline
    • 6.1.1.1 Asset Inventory
    • 6.1.1.2 Asset-Level Profiles
    • 6.1.1.3 Sponsor Analysis
  • 6.1.2 Phase I Pipeline
    • 6.1.2.1 Asset Inventory
    • 6.1.2.2 Asset-Level Profiles
    • 6.1.2.3 Sponsor Analysis
  • 6.1.3 Phase II Pipeline
    • 6.1.3.1 Asset Inventory
    • 6.1.3.2 Asset-Level Profiles
    • 6.1.3.3 Sponsor Analysis
  • 6.1.4 Phase III Pipeline
    • 6.1.4.1 Asset Inventory
    • 6.1.4.2 Asset-Level Profiles
    • 6.1.4.3 Sponsor Analysis
  • 6.1.5 Filed and Under Review Assets
    • 6.1.5.1 Regulatory Status Review
    • 6.1.5.2 Approval Readiness Assessment
• 6.2 Pipeline Segmentation by Mechanism of Action
  • 6.2.1 Orexin Pathway Assets
  • 6.2.2 GABAergic Assets
  • 6.2.3 Melatonin-Based Assets
  • 6.2.4 Circadian Rhythm Assets
  • 6.2.5 Other Novel Mechanisms
• 6.3 Pipeline Segmentation by Modality
  • 6.3.1 Small Molecule Assets
  • 6.3.2 Biologic Assets
  • 6.3.3 RNA-Based Assets
  • 6.3.4 Cell and Gene Therapy Assets
• 6.4 Asset-Level Competitive Profiles
  • 6.4.1 Molecule Overview
  • 6.4.2 Developer Company
  • 6.4.3 Mechanism of Action
  • 6.4.4 Clinical Phase
  • 6.4.5 Clinical Trial Status
  • 6.4.6 Competitive Positioning
  • 6.4.7 Regulatory Outlook
  • 6.4.8 Commercial Potential

7. Probability of Success and Risk Analysis

• 7.1 Probability Modeling Framework
  • 7.1.1 Modeling Assumptions
  • 7.1.2 Historical Benchmark Methodology
  • 7.1.3 Risk Adjustment Methodology
• 7.2 Phase Transition Analysis
  • 7.2.1 Preclinical to Phase I
  • 7.2.2 Phase I to Phase II
  • 7.2.3 Phase II to Phase III
  • 7.2.4 Phase III to Approval
  • 7.2.5 Overall Probability of Approval
• 7.3 Attrition Intelligence
  • 7.3.1 Historical Attrition Rates
  • 7.3.2 Mechanism-Specific Attrition
  • 7.3.3 Sponsor-Specific Attrition
  • 7.3.4 Clinical Failure Drivers
• 7.4 Risk-Adjusted Pipeline Valuation
  • 7.4.1 Asset-Level Risk Scores
  • 7.4.2 Portfolio Risk Assessment
  • 7.4.3 Probability-Weighted Opportunity Analysis

8. Launch Timeline and Commercial Potential

• 8.1 Approval Timeline Forecasts
  • 8.1.1 Near-Term Approval Candidates
  • 8.1.2 Mid-Term Approval Candidates
  • 8.1.3 Long-Term Approval Candidates
• 8.2 Launch Sequencing Analysis
  • 8.2.1 Expected Market Entry Timelines
  • 8.2.2 Competitive Launch Windows
  • 8.2.3 Market Access Readiness
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Addressable Market Potential
  • 8.3.2 Peak Sales Potential
  • 8.3.3 Probability-Weighted Revenue Potential
  • 8.3.4 Commercial Risk Assessment

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Competitive Assessment
  • 9.1.1 Pipeline Breadth Analysis
  • 9.1.2 Pipeline Depth Analysis
  • 9.1.3 Innovation Strength Assessment
  • 9.1.4 Development Execution Assessment
• 9.2 Competitive Positioning Matrix
  • 9.2.1 Market Leaders
  • 9.2.2 Emerging Challengers
  • 9.2.3 Niche Innovators
  • 9.2.4 Early-Stage Entrants
• 9.3 Asset Concentration Analysis
  • 9.3.1 Assets by Company
  • 9.3.2 Assets by Mechanism
  • 9.3.3 Assets by Development Phase
  • 9.3.4 Competitive White Spaces

10. Geographic Analysis

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 Latin America
• 10.5 Middle East & Africa

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

For each country:

Clinical Trial Activity

Regulatory Timelines

Key Sponsors

Innovation Ecosystem

Development Opportunities

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
  • 12.1.1 Asset Licensing Deals
  • 12.1.2 Regional Licensing Transactions
  • 12.1.3 Commercialization Partnerships
• 12.2 Co-Development Collaborations
  • 12.2.1 Pharma-Pharma Partnerships
  • 12.2.2 Pharma-Biotech Collaborations
  • 12.2.3 Academic Collaborations
• 12.3 Mergers and Acquisitions
  • 12.3.1 Asset Acquisitions
  • 12.3.2 Company Acquisitions
  • 12.3.3 Strategic Portfolio Transactions
• 12.4 Investment Trends
  • 12.4.1 Venture Capital Activity
  • 12.4.2 Private Equity Investments
  • 12.4.3 Public Financing Activity
  • 12.4.4 Government Funding Programs

13. Future Outlook and Strategic Insights

• 13.1 Future Innovation Outlook
  • 13.1.1 Emerging Mechanisms
  • 13.1.2 Precision Sleep Medicine
  • 13.1.3 Combination Therapy Opportunities
• 13.2 Competitive Evolution Outlook
  • 13.2.1 Future Market Leaders
  • 13.2.2 Pipeline Consolidation Trends
  • 13.2.3 Strategic Partnership Outlook
• 13.3 Strategic Recommendations
  • 13.3.1 Recommendations for Developers
  • 13.3.2 Recommendations for Investors
  • 13.3.3 Recommendations for Business Development Teams

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Data Collection Process
  • 14.1.2 Validation Methodology
  • 14.1.3 Quality Assurance Framework
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Regulatory Filings
  • 14.2.4 Company Pipeline Disclosures
  • 14.2.5 Investor Presentations
• 14.3 Forecasting Methodology
  • 14.3.1 Probability Modeling
  • 14.3.2 Revenue Forecasting
  • 14.3.3 Risk Adjustment Framework
• 14.4 Definitions and Classification Criteria
  • 14.4.1 Phase Classification Rules
  • 14.4.2 Mechanism Classification Rules
  • 14.4.3 Modality Classification Rules
  • 14.4.4 Asset Inclusion Criteria
• 14.5 Assumptions and Limitations
  • 14.5.1 Forecast Assumptions
  • 14.5.2 Data Constraints
  • 14.5.3 Analytical Limitations
  • 14.5.4 Update Methodology